FDA: Veozah, the First Hormone-Free Hot Flash Drug, Issued a Black Box Warning
FDA: Veozah, the First Hormone-Free Hot Flash Drug, Issued a Black Box Warning \ By India Edwards, HealthDay Reporter WEDNESDAY, Dec. 18, 2024 -- The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah , a medication used to relieve hot flashes in menopausal women, due to rare but potentially severe liver risks. In a new communication issued Dec. 17, the FDA advised that women taking Veozah should undergo regular blood testing to monitor liver health. A news release says that warning signs of liver injury can include fatigue, nausea, vomiting, dark urine, light-colored stools, or yellowing of the skin or eyes. Patients experiencing these symptoms should immediately stop taking the medication and consult with their doctor. “It’s important to note that the overall benefit-risk of Veozah has not changed and remains positive, but we want to further ensure that patients and healthcare provide...